Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
4
Confirmed lead rounds
—
4 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$542M
4 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B1

By primary sector

Biotech4

By country

United States4

Rounds

4 in this selection
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed
SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B
Role not disclosed
Cellares

Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network.

$257MSeries D
Role not disclosed